Company news

Racura Oncology Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

First Patient Safely Combine Dosed in Phase 1 RC220 Trial

June 18, 2025

First Patient Dosed Safely in RC220 Phase 1 Trial

April 30, 2025

March 2025 Quarterly Activity Report and Appendix 4C

April 22, 2025

Enrolment Opened at Second Site for RC220 Phase 1 Trial

April 21, 2025

RC220 Phase 1 Trial Opens for Patient Enrolment

April 2, 2025

Race Initiates First AU Site for Phase 1 Solid Tumour Trial

March 27, 2025

Ethics approval received for RC220 Phase 1 Trial

March 13, 2025

S&P DJI Announces March 2025 Quarterly Rebalance

March 7, 2025

Race Signs Contract for Phase 1 Trial of RC220

March 4, 2025

Quarterly Activity Report and Appendix 4C

January 30, 2025

Race Receives $5.25m RD Tax Refund for Financial Year 2024

December 16, 2024

Race Submits Human Ethics for RC220 Phase 1 Trial

December 4, 2024

Race Discovers Multiple Novel FTO Inhibitor Candidates

November 20, 2024

Race Oncology Board Renewal Update

September 1, 2024

Bisantrene Phase 2 AML Trial Successful Concludes

July 29, 2024

RC220 GLP Non-clinical Toxicology Program Successful

June 25, 2024

Race Appoints George Clinical for Phase 1 Trial of RC220

June 19, 2024

FDA RPD Designation Granted for RC220 Bisantrene

June 17, 2024

Bisantrene Highly Active in a Multiple Myeloma Mouse Model

June 12, 2024

US FDA Orphan Drug Designation Awarded to RC220 Bisantrene

June 10, 2024

Bisantrene with Decitabine Enhances Cancer Cell Killing

May 13, 2024

Quarterly Activity Report & Appendix 4C

April 18, 2024

RC220 cGMP Manufacturing Complete

March 25, 2024

Bisantrene shows potent anticancer activity in AML models

March 5, 2024

S&P DJI Announces March 2024 Quarterly Rebalance

March 1, 2024

Race Receives $4.0m R&D Tax Refund for Financial Year 2023

February 27, 2024

December 2023 Preclinical & Clinical Program Update

December 29, 2023

Bonus Options Prospectus

November 21, 2023

Updated Strategy and Investor Presentation

November 21, 2023

Dr Daniel Tillett appointed CEO of Race Oncology

November 21, 2023

RC220 Meets Quality Specifications

November 8, 2023

Impressive Bisantrene Phase 2 AML Clinical Results

November 6, 2023

Trading Halt

November 2, 2023

RC220 Peripheral Infusion Safety Confirmed

October 16, 2023

RC220 Toxicology and Safety Pharmacology Studies Initiated

October 4, 2023

Bisantrene cGMP API Manufacturing Completed at Laurus Labs

September 26, 2023

Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells

September 20, 2023

Race Board and Management Team Changes

August 21, 2023

Race Strategic Update August 2023

August 8, 2023

Race Receives Additional $1.66m R&D Tax Refund for FY 2022

July 13, 2023

Race executes agreement with Ardena for GMP manufacturing

July 11, 2023

Race global agreement with City of Hope to access FTO IP

July 9, 2023

H1 2023 Preclinical and Clinical Programs Update

July 6, 2023

Letter to Shareholders

June 15, 2023

Race releases complete cardio-protection data & video

April 13, 2023

Race releases cardioprotection market potential data

April 3, 2023

Race Receives $1.48m R&D Tax Refund for Financial Year 2022

March 27, 2023

Race Leadership Changes

March 23, 2023

Pause in Trading

March 21, 2023

Race Executes Contracts to Commence Breast Cancer Trial

March 12, 2023

← Newer news releases · Older news releases →

Decks

The 5 newest of 33 decks. Every deck is listed under its year.